Selective requirement for Mediator MED23 in Ras-active lung cancer

K-RAS–activating mutations occur frequently in non-small cell lung cancer, leading to aberrant activation of the Ras–MAPK signaling pathway that contributes to the malignant phenotype. However, the development of Ras-targeted therapeutics remains challenging. Here, we show that MED23, a component of...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Yang, Xu, Zhao, Meng, Xia, Min, Liu, Yuting, Yan, Jun, Ji, Hongbin, Wang, Gang
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: National Academy of Sciences 2012
Konular:
PNAS Plus
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3478617/
https://ncbi.nlm.nih.gov/pubmed/22988093
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1204311109
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller